Literature DB >> 11840325

Id proteins at the cross-road of development and cancer.

A Lasorella1, T Uo, A Iavarone.   

Abstract

A large body of evidence has been accumulated that demonstrates dominant effects of Id proteins on different aspects of cellular growth. Generally, constitutive expression of Id not only blocks cell differentiation but also drives proliferation. In some settings, it is sufficient to render cells immortal or induce oncogenic transformation. The participation of Id proteins in advanced human malignancy, where they are frequently deregulated, has been dramatically bolstered by the recent discovery that Id exert pivotal contributions to many of the essential alterations that collectively dictate malignant growth. Relentless proliferation associated with self-sufficiency in growth signals and insensitivity to growth inhibitory signals, sustained neoangiogenesis, tissue invasiveness and migration capabilities of tumor cells all share dependency on the unlimited availability of Id proteins. It is remarkable that many of these features recapitulate those physiologically propelled by Id proteins to support normal development. We propose that the participation of Id in multiple fundamental traits of cancer may be the basis for unprecedented therapeutic opportunities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11840325     DOI: 10.1038/sj.onc.1205093

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  99 in total

1.  Loss of Id2 potentiates the tumorigenic effect of Rb inactivation in a mouse model of retinoblastoma.

Authors:  Solange Landreville; Duanduan Ma; Jun Wu; J William Harbour
Journal:  Curr Eye Res       Date:  2010-05       Impact factor: 2.424

Review 2.  Helix-loop-helix proteins in mammary gland development and breast cancer.

Authors:  Pierre-Yves Desprez; Tomoki Sumida; Jean-Philippe Coppé
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

3.  Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation.

Authors:  Junwon Lee; Kabsun Kim; Jung Ha Kim; Hye Mi Jin; Han Kyung Choi; Seoung-Hoon Lee; Hyun Kook; Kyung Keun Kim; Yoshifumi Yokota; Soo Young Lee; Yongwon Choi; Nacksung Kim
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

4.  The protein ENH is a cytoplasmic sequestration factor for Id2 in normal and tumor cells from the nervous system.

Authors:  Anna Lasorella; Antonio Iavarone
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

5.  Expression of Id1 in adult, regenerating and developing pancreas.

Authors:  Hong Hua; Nora Sarvetnick
Journal:  Endocrine       Date:  2008-03-06       Impact factor: 3.633

6.  Tetraspanin TSPAN12 regulates tumor growth and metastasis and inhibits β-catenin degradation.

Authors:  Konstantin Knoblich; Hong-Xing Wang; Chandan Sharma; Anne L Fletcher; Shannon J Turley; Martin E Hemler
Journal:  Cell Mol Life Sci       Date:  2013-08-18       Impact factor: 9.261

7.  SHIP1 regulates MSC numbers and their osteolineage commitment by limiting induction of the PI3K/Akt/β-catenin/Id2 axis.

Authors:  Sonia Iyer; Dennis R Viernes; John D Chisholm; Bryan S Margulies; William G Kerr
Journal:  Stem Cells Dev       Date:  2014-07-03       Impact factor: 3.272

8.  Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.

Authors:  M J Gray; N A Dallas; G Van Buren; L Xia; A D Yang; R J Somcio; P Gaur; L S Mangala; P E Vivas-Mejia; F Fan; A M Sanguino; G E Gallick; G Lopez-Berestein; A K Sood; L M Ellis
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

9.  ID4 is frequently downregulated and partially hypermethylated in prostate cancer.

Authors:  Anna Vinarskaja; Wolfgang Goering; Marc Ingenwerth; Wolfgang A Schulz
Journal:  World J Urol       Date:  2011-09-01       Impact factor: 4.226

Review 10.  Transcriptional control of the cell cycle in mammary gland development and tumorigenesis.

Authors:  Ricardo D Coletta; Paul Jedlicka; Arthur Gutierrez-Hartmann; Heide L Ford
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.